Bone quality: Getting closer to a definition

Journal of Bone and Mineral Research

Volumn 17, Issue 7, 2002, Pages 1148-1150

  Watts, Nelson B ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; PARATHYROID HORMONE; RALOXIFENE; RISEDRONIC ACID; DRUG DERIVATIVE; ETIDRONIC ACID;

BONE DENSITY; BONE MASS; BONE MINERAL; BONE STRUCTURE; DENSITOMETRY; DRUG MECHANISM; EDITORIAL; FRACTURE; HUMAN; NONHUMAN; OSTEOPOROSIS; SEMANTICS; ANIMAL; DRUG EFFECT; GENERAL APPARATUS, EQUIPMENT AND SUPPLIES; LUMBAR VERTEBRA; MINIPIG; NOTE; PATHOPHYSIOLOGY; RADIOGRAPHY; SPINE FRACTURE;

ANIMALS; BONE DENSITY; ETIDRONIC ACID; HUMANS; LUMBAR VERTEBRAE; OSTEOPOROSIS; SPINAL FRACTURES; SWINE, MINIATURE; TOMOGRAPHY SCANNERS, X-RAY COMPUTED;

EID: 0035991189     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.2002.17.7.1148     Document Type: Editorial

References (27)

1. Fracture prediction for the proximal femur using finite element models: Part I - Linear analysis
2. Ultrasound and densitometry of the calcaneus correlate with the failure loads of cadaveric femurs
3. Prediction of vertebral strength in vitro by spinal bone densitometry and calcaneal ultrasound
4. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures
5. Age and bone mass as predictors of fracture in a prospective study
6. Do men and women fracture bones at similar bone densities?
7. Perspective: Assessing bone density in men
8. A population-based study of fracture incidence in southern Tasmania: Lifetime fracture risk and evidence for geographic variations within the same country
9. World-wide projections for hip fracture
10. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
11. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The Prevent Recurrence of Osteoporotic Fractures study
12. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene-results from a 3-year randomized clinical trial
13. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis
14. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis
15. Risedronate reduces the risk of clinical vertebral fractures in just 6 months
16. Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial
17. Raloxifene reduces vertebral fractures at one year
18. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis
19. Effect of risedronate on the risk of hip fracture in elderly women
20. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy
21. Prophylaxis and treatment of osteoporosis
22. Preexisting fractures and bone mass predict vertebral fracture incidence in women
23. Risk of new vertebral fracture in the year following a fracture
24. Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography
25. BMD change explains only a fraction of the observed fracture risk reduction in risedronate-treated patients
26. Bone turnover matters: The raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density
27. Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture